Physiologically based pharmacokinetic model to assess the influence of blinatumomab-mediated cytokine elevations on cytochrome P450 enzyme activity

CPT: Pharmacometrics and Systems Pharmacology

Volumn 4, Issue 9, 2015, Pages 507-515

  Xu, Y ^a   Hijazi, Y ^b   Wolf, A ^b   Wu, B ^a   Sun, Y N ^a   Zhu, M ^a  

^a AMGEN INC   (United States)

^b Amgen Research GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLINATUMOMAB; CAFFEINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; MIDAZOLAM; SIMVASTATIN; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AREA UNDER THE CURVE RATIO; ARTICLE; BLOOD-TO-PLASMA RATIO; CONCENTRATION AT STEADY-STATE; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG CLEARANCE; EC50; ELIMINATION RATE CONSTANT; ENZYME ACTIVITY; FEMALE; HUMAN; INTRINSIC CLEARANCE; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; NONHODGKIN LYMPHOMA; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RISK ASSESSMENT; VOLUME OF DISTRIBUTION; VOLUME OF DISTRIBUTION AT STEADY-STATE;

EID: 84942552466     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.12003     Document Type: Article

References (39)

1. Bargou, R., et al., Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974-977 (2008).
2. Nagorsen, D., &, Baeuerle, P.A., Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp. Cell Res. 317, 1255-1260 (2011).
3. Gore, L., et al., Cytological and molecular remissions with blinatumomab treatment in second or later bone marrow relapse in pediatric acute lymphoblastic leukemia (ALL). American Society of Clinical Oncology Annual Meeting; May 31-June 4; Chicago, IL; 2013.
4. Hijazi, Y., et al., Blinatumomab exposure and pharmacodynamic response in patients with non-Hodgkin lymphoma (NHL). J. Clin. Oncol. 31, abstract 3051 (2013).
5. Klinger, M., et al., Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119, 6226-6233 (2012).
6. Topp, M.S., et al., Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL). J. Clin. Oncol. 32, abstract 7005 (2014).
7. Viardot, A., et al., Open-label phase 2 study of the bispecific T-cell engager (BiTE) blinatumomab in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood 122, 1811 (2013).
8. Dreier, T., et al., T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J. Immunol. 170, 4397-4402 (2003).
9. Hoffmann, P., et al., Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int. J. Cancer 115, 98-104 (2005).
10. Schub, A., et al., Immunopharmacodynamic responses following treatment with the bispecific T-cell engager antibody blinatumomab among patients with relapsed/refractory B-precursor acute lymphoblastic leukemia. 18th Congress of the European Hematology Association June 13-16; Stockholm, Sweden; 2013.
11. Haas, C.E., Kaufman, D.C., Jones, C.E., Burstein, A.H., &, Reiss, W., Cytochrome P450 3A4 activity after surgical stress. Crit. Care Med. 31, 1338-1346 (2003).
12. Lee, J.I., Zhang, L., Men, A.Y., Kenna, L.A., &, Huang, S.M., CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin. Pharmacokinet. 49, 295-310 (2010).
13. Nakai, K., et al., Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients. Drug Metab. Dispos. 36, 1786-1793 (2008).
14. Jamei, M., et al., The Simcyp population-based ADME simulator. Expert Opin. Drug Metab. Toxicol. 5, 211-223 (2009).
15. Machavaram, K.K., et al., A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6. Clin. Pharmacol. Ther. 94, 260-268 (2013).
16. 2/d is tolerable and highly effective. Blood (ASH Annual Meeting Abstracts) 116, 2880 (2010).
17. Baeuerle, P.A., &, Reinhardt, C., Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 69, 4941-4944 (2009).
18. Dickmann, L.J., Patel, S.K., Rock, D.A., Wienkers, L.C., &, Slatter, J.G., Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab. Dispos. 39, 1415-1422 (2011).
19. Rowland Yeo, K., Jamei, M., Yang, J., Tucker, G., &, Rostami-Hodjegan, A., Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-the effect of diltiazem on the time-course of exposure to triazolam. Eur. J. Pharm. Sci. 39, 298-309 (2010).
20. Simcyp. A Guide for IVIVE and PBPK/PD Modeling Using the Simcyp Population Based Simulator 231-249 (Simcyp, Sheffield, UK, 2012).
21. Paine, M.F., et al., The human intestinal cytochrome P450 "pie." Drug Metab. Dispos. 34, 880-886 (2006).
22. Uno, S., Kawase, A., Tsuji, A., Tanino, T., &, Iwaki, M., Decreased intestinal CYP3A and P-glycoprotein activities in rats with adjuvant arthritis. Drug Metab. Pharmacokinet. 22, 313-321 (2007).
23. Schmitt, C., Kuhn, B., Zhang, X., Kivitz, A.J., &, Grange, S., Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin. Pharmacol. Ther. 89, 735-740 (2011).
24. Topp, M.S., et al., Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed/refractory B-precursor ALL. J. Clin. Oncol. 30, abstract 6500 (2012).
25. U.S. Food and Drug Administration Center for Drug Evaluation and Research. Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations (Silver Springs, MD, 2012).
26. Gorski, J.C., et al., In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin. Pharmacol. Ther. 67, 32-43 (2000).
27. Huhn, R.D., et al., Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers. Clin. Pharmacol. Ther. 62, 171-180 (1997).
28. Azam, Y.J., Machavaram, K.K., &, Rostami-Hodjegan, A., The modulating effects of endogenous substances on drug metabolising enzymes and implications for inter-individual variability and quantitative prediction. Curr. Drug Metab. 15, 599-619 (2014).
29. Thummel, K.E., &, Wilkinson, G.R., In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 38, 389-430 (1998).
30. Rowland Yeo, K., Walsky, R.L., Jamei, M., Rostami-Hodjegan, A., &, Tucker, G.T., Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. Eur. J. Pharm. Sci. 43, 160-173 (2011).
31. Xu, Y., Zhou, Y., Hayashi, M., Shou, M., &, Skiles, G.L., Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs. Drug Metab. Dispos. 39, 1139-1148 (2011).
32. Rhodes, B., Furnrohr, B.G., &, Vyse, T.J., C-reactive protein in rheumatology: biology and genetics. Nat. Rev. Rheumatol. 7, 282-289 (2011).
33. Rivory, L.P., Slaviero, K.A., &, Clarke, S.J., Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br. J. Cancer 87, 277-280 (2002).
34. Slatter, J.G., Wienkers, L.C., &, Dickmann, L.J., Drug interactions of cytokines and anticytokine therapeutic proteins. In Drug-Drug Interactions for Therapeutic Biologics (eds., Zhou, H,., Meibohm, B.,) 215-237 (John Wiley and Sons, Hoboken, NJ, 2013).
35. Harvey, R.D., &, Morgan, E.T., Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. Clin. Pharmacol. Ther. 96, 449-457 (2014).
36. Wang, J., Wang, Y.M., &, Ahn, H.Y., Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications. AAPS J. 16, 938-947 (2014).
37. Davila, M.L., et al., Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra225 (2014).
38. Le Vee, M., Lecureur, V., Stieger, B., &, Fardel, O., Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab. Dispos. 37, 685-693 (2009).
39. Shitara, Y., Sato, H., &, Sugiyama, Y., Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol. 45, 689-723 (2005).